LDX (ASX) LDX Discussion

Originally posted by Quest09: ↑

Looking forward to receiving news on these price sensitive catalysts.

Due as early as in December 2024 (only ~ 2 weeks away).

Expand

Originally posted by Quest09: ↑

Just last month (October), LDX was able to attract a significant amount of institutional funds from at least two professional investment companies (Tenmile and Ryder Capital). The two investment companies together now own 36.9% of LDX. IMO, both of these two investment companies would have done their due diligence checks before agreeing to invest, and IMO they also would have had direct access to quiz and question senior management about LDX's business plans/strategy.

IMO, the fact that two separate institutional investors decided to buy up a large portion of LDX shares can be an indicator of the upside potential available in LDX shares at current prices.

Expand

Originally posted by Quest09: ↑

The US Food and Drug Administration (FDA) is the govt department responsible for granting the LDX CLIA waiver (as per below image).

A successful CLIA waiver will reportedly open up the number of potential sites which can buy FebriDx from 18,000 sites pre-waiver, to 270,000 sites post-waiver. In monetary terms the total available market (TAM) will increase from US $118 million dollars per annum, pre CLIA waiver, to US $1.7 billion per annum, post CLIA waiver (see image below).

So lets see what the FDA has to say about the global problem of antimicrobial resistance. The FDA happens to have a whole webpage addressing this important global problem: https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistance

Some key points from the FDA
The FDA's role and strategic approach to combating antimicrobial resistance is shown below (it seems like the FDA's policy on AMR is completely aligned with LDX's aims with FebriDx):

Expand

Decent Breakout today on relatively high volume..

This strong move upwards is likely to continue tomorrow IMO.

We are about to reclaim a lot that upside potential which we recently gave up and which is currently available with LDX IMO.......and if one of our expected (or unexpected) announcements hit, then who knows what kind of price levels we can achieve.

LDX looking strong. =)

Originally posted by Quest09: ↑

WHO Director-General Dr Tedros talks about the URGENT need to tackle antimicrobial resistance (AMR).

Quote: "concrete actions needed to tackle AMR, this includes.........reducing the unnecessary use of antimicrobials in healthcare and agriculture"

This is precisely the problem LDX is working on with FebriDX. With such a massive global focus on this problem, IMO, LDX is very well placed to successfully achieve a PLA code reimbursement on FebriDX (i.e. USA govt covering part/whole of medical clinic's cost of buying and using FebriDx), and then also successfully achieving the FDA CLIA waiver (meaning many more USA clinics are able to freely use the product).

See below links for more details.

IMO, LDX has significant upside potential.

Expand

Originally posted by Quest09: ↑

Article from the Australian Medical Association.

Quote: " World AMR Awareness Week alerts us to one of the most serious global health threats of the 21st century "

IMO, LDX has identified a highly notable need in the fight against antimicrobial resistance and has established itself with a ready to use product (FebriDx) within a market that is desperate for solutions.

IMO, the fact that the US Department of Health and Human Services (BARDA) has provided LDX with up to US 8.3 million in funding and support is a reflection of the endorsement that LDX has from policy makers in the fight against AMR.

IMO, that support will only become more substantive overtime, and will highly likely come more governments around the world, including Australia.

Link to Article: https://www.ama.com.au/media/awareness-week-highlights-danger-drug-resistant-superbugs

Expand

Originally posted by Quest09: ↑

LDX to be presenting at the Bell Potter Healthcare Conference. LDX's presentation is on Wednesday 20 November.

Good to see LDX working hard to get their name and products in front new and existing potential customers and investors.

Expand

No.	Vol.	Price($)
2	300000	7.2¢

No.

Vol.

Price($)

300000

7.2¢

Price($)	Vol.	No.
7.3¢	61016	1

Price($)

Vol.

No.

7.3¢

61016

No.	Vol.	Price($)
2	300000	0.072
6	405951	0.071
4	880000	0.070
4	262000	0.069
6	1838000	0.068

No.

Vol.

Price($)

300000

0.072

405951

0.071

880000

0.070

262000

0.069

1838000

0.068

Price($)	Vol.	No.
0.073	61016	1
0.074	178182	3
0.075	1357494	4
0.076	430228	7
0.077	641000	9

Price($)

Vol.

No.

0.073

61016

0.074

178182

0.075

1357494

0.076

430228

0.077

641000

(20min delay)
Last 7.3¢		Change 0.006(8.96%)		Mkt cap ! $54.64M

Open	High	Low	Value	Volume
6.8¢	7.5¢	6.8¢	$874.7K	11.97M

Neurizon inks $1.5M loan against R&D Tax Rebate

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

Haranga jumps +7% on Lincoln acquisition

Ionic Rare Earths falls -7% as momentum slips on vague production update

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Neurizon inks $1.5M loan against R&D Tax Rebate

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

Haranga jumps +7% on Lincoln acquisition

Ionic Rare Earths falls -7% as momentum slips on vague production update

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News